Transocean Ltd. (NYSE:RIG) [Trend Analysis] surged reacts as active mover, shares a gain 6.09% to traded at $10.63 and the percentage gap among open changing to regular change was 0.10%. Billionaire investor, Carl Icahn slashed his stake in Offshore drilling firm Transocean Ltd. (RIG) in order to recognize a capital loss for tax planning purposes, a filing with the Securities And Exchange Commission on Wednesday revealed. Icahn had accumulated 5.9 percent stake in Transocean in November 2013, but now reduced it to 1.5 percent, according to the filing.
His companies beneficially own, in the aggregate, 5.48 Million shares. At the end of the June quarter, he had held 21.48 million shares. Icahn additional stated that both of his director designees would continue to serve on Transocean’s board on the firm’s request. The firm’s current ratio calculated as 1.90 for the most recent quarter. The firm past twelve months price to sales ratio was 0.68 and price to cash ratio remained 1.80. As far as the returns are concern, the return on equity was recorded as 8.70% and return on investment was 5.10% while its return on asset stayed at 4.80%. The firm has total debt to equity ratio measured as 0.55.
Alcoa Inc. (NYSE:AA) [Trend Analysis] attempts to attain leading position in street, Shares price changes as it 0.81% to close at $9.96 with the total traded volume of 26.83 Million shares. Agilent Technologies Inc. (A) reported that it has inked a accord with Chinese diagnostics firm Burning Rock. Under the contract, Burning Rock will develop cancer diagnostics in China based on the Agilent SureSelect target enrichment system. Agilent offers target enrichment for next-generation DNA sequencing.
Burning Rock is a fast-growing firm focused on developing cancer diagnostics based on DNA sequencing. Yusheng Han, the founder and chief executive officer of Burning Rock, stated, “Alliance among our two companies will provide additional high-quality molecular diagnostic solutions based on next-generation sequencing, comprising non-invasive testing, relapse monitoring, early-stage diagnosis and cancer susceptibility.” The firm has institutional ownership of 72.30%, while insider ownership included 0.10%. Its price to sales ratio ended at 0.62. AA attains analyst recommendation of 2.40 with week performance of 1.84%.